Skip to main content
Clinical Trials/NCT01089283
NCT01089283
Unknown
Not Applicable

I123 DAT-SCAN and PET-CT FDG to Assess Brain Function of Parkinson Patients With Different Genetic Characteristic

Tel-Aviv Sourasky Medical Center1 site in 1 country80 target enrollmentMarch 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Parkinson Disease
Sponsor
Tel-Aviv Sourasky Medical Center
Enrollment
80
Locations
1
Last Updated
16 years ago

Overview

Brief Summary

Parkinson disease is one of the most common neurodegenerative illnesses. The disease is characterized by decrease in dopamine levels and decrease in the number of dopaminergic neurons and dopamine receptors. There are gene mutations that increase the risk for the disease. Two of those mutations are on the LRRK2 gene and on GBA gene. It is yet unknown if there is a difference between the metabolic brain function of Parkinson patients that carry one of the two mutations to Parkinson patients with no known mutation.

Participants: diagnosed Parkinson patients that carry a gene mutation in either LRRK2 or GBA genes, Parkinson patients with no known mutation and healthy volunteers as a control group.

The participants will go through both examinations DAT SCAN and PET CT SCAN at the Tel Aviv Sourasky Medical Center Nuclear Medicine Institute.

The examination results will be given to the participants by a doctor from the neurology department.

Registry
clinicaltrials.gov
Start Date
March 2010
End Date
March 2011
Last Updated
16 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • diagnosed Parkinson patients with known genetic characteristics

Exclusion Criteria

  • patients unable to understand and sign an informed consent
  • patients in medical condition that does not allow them to stay still during the examination

Outcomes

Primary Outcomes

Not specified

Study Sites (1)

Loading locations...

Similar Trials